[1]王 伟,曹小宁,顾勇亮,等.CDK5与喹啉酮类抑制剂相互作用的分子模拟研究[J].南京师大学报(自然科学版),2013,36(02):56-60.
 Wang Wei,Cao Xiaoning,Gu Yongliang,et al.Study on Binding of Quinolinone Inhibitors to CDK5 Based on Molecular Dynamics Simulation[J].Journal of Nanjing Normal University(Natural Science Edition),2013,36(02):56-60.
点击复制

CDK5与喹啉酮类抑制剂相互作用的分子模拟研究()
分享到:

《南京师大学报(自然科学版)》[ISSN:1001-4616/CN:32-1239/N]

卷:
第36卷
期数:
2013年02期
页码:
56-60
栏目:
化学
出版日期:
2013-06-30

文章信息/Info

Title:
Study on Binding of Quinolinone Inhibitors to CDK5 Based on Molecular Dynamics Simulation
文章编号:
1001-4616(2013)02-0056-05
作者:
王 伟曹小宁顾勇亮朱小蕾
南京工业大学化学化工学院,材料化学工程国家重点实验室,江苏 南京 210009
Author(s):
Wang WeiCao XiaoningGu YongliangZhu Xiaolei
State Key Laboratory of Materials-Oriented Chemical Engineering,College of Chemistry and Chemical Engineering, Nanjing University of Technology,Nanjing 210009,China
关键词:
喹啉酮类抑制剂细胞色素依赖蛋白激酶-5分子动力学模拟结合自由能
Keywords:
quinolinone inhibitorsCDK5molecular dynamics simulationbinding free energy
分类号:
O643.1
文献标志码:
A
摘要:
本文采用分子对接、分子动力学模拟(MD)和结合自由能计算等方法研究了3种喹啉酮类抑制剂与CDK5的相互作用,并且分析和讨论了药物与其周围残基之间的氢键和疏水作用.模拟结果还表明M1和M2与CDK5的结合模式很相似,但残基分解分析表明残基Ile10对于区分M1和M2之间不同的生物活性起到关键的作用.然而,M3的结合模式与M1或M2相比却有一些不同,其中它与残基Asn144之间的静电作用在结合过程中起到了关键的作用.本文的工作对于以后设计新型的有较高选择性的CDK5抑制剂具有一定的指导意义.
Abstract:
Molecular docking,molecular dynamics(MD)simulations,and binding free energy analysis are performed to investigate the interactions between three quinolinone inhibitors and CDK5.The hydrogen bonding and hydrophobic interactions between inhibitors and adjacent residues are analyzed and discussed.The results illustrate that the binding modes of M1 and M2 with CDK5 are quite similar.And the energy decomposition analysis reveals that the residue I10 is one key residue for the different bioactivity between M1 and M2.However,M3 in M3/CDK5 exhibits a different binding mode compared to M1 or M2,the electrostatic energy between M3 and residue Asn144 plays a key role in the binding.The results of our work may be helpful for the design of novel and selective CDK5 inhibitors.

参考文献/References:

[1] Mapelli M,Musacchio A.The structural perspective on CDK5[J].Neurosignals,2003,12:164-172.
[2]Dhavan R,Tsai L H.A Decade of CDK5[J].Nat Rev Mol Cell Biol,2001,2:749-759.
[3]Zhang B,Su Z C,Tay T E,et al.Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations[J].J Mol Model,2010,16:1 159-1 168.
[4]Cicenas J,Valius M.The CDK inhibitors in cancer research and therapy[J].J Cancer Res Clin Oncol,2011,137:1 409-1 418.
[5]Tarricone C,Dhavan R,Peng J.Structure and regulation of the CDK5-p25nck5a complex[J].Mol Cell,2001,8(3):657-669.
[6]Dhariwala F A,Rajadhyaksha M S.An unusual member of the Cdk family:Cdk5[J].Cell Mol Neurobiol,2008,28(3):351-369.
[7]Pitchuanchom S,Boonyarat C,Forli S,et al.Cyclin-dependent kinases 5 template:useful for virtual screening[J].Comput Biol Med,2012,42(1):106-111.
[8]Glicksman M A,Cuny G D,Liu M,et al.New approaches to the discovery of cdk5 inhibitors[J].Curr Alzheimer Res,2007,4(5):547-549.
[9]Leost M,Schultz C,Link A,et al.Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25[J].Eur J Biochem,2000,267(19):5 983-5 994.
[10]Beauchard A,Ferandin Y,Frère S,et al.Synthesis of novel 5-substituted indirubins as protein kinases inhibitors[J].Bioorg Med Chem,2006,14(18):6 434-6 443.
[11]Chang Y T,Gray N S,Rosania G R,et al.Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors[J].Chem Biol,1999,6(6):361-375.
[12]Rzasa R M,Kaller M R,Liu G,et al.Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors[J].Bioorg Med Chem,2007,15(20):6 574-6 594.
[13]Frisch M J,Trucks,G W,Schlegel H B,et al.Gaussian 09,Revision A.02[M].Wallingford:Gaussian Inc,2009.
[14]Case D A,Cheatham T A,Simmerling C L,et al.AMBER 10[M].San Francisco:University of California,2008.

备注/Memo

备注/Memo:
收稿日期:2013-01-08.
基金项目:国家自然科学基金项目(21276122,21136001,20876073).
通讯联系人:朱小蕾,教授,博士生导师,研究方向:分子模拟.E-mail:xlzhu@njut.edu.cn
更新日期/Last Update: 2013-06-30